GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort

AstraZeneca

Status: Not yet enrolling

Conditions: Gynaecological Cancers

Treatments: Diagnostic Test: HER-2 Test

Study type: Observational

Funder types: Industry

Identifiers

NCT07101081

D9673R00061

Details and patient eligibility

About

Adult patients with gynecologic cancer (endometrial, ovarian, cervical, vulvar and vaginal cancers) treated at Oncoclínicas & CO sites will be enrolled for primary tumor immunohistochemistry (IHC) analysis. When sufficient paraffin tissue is available for biomarker testing, slides will be sent from partner Pathology Labs of the OC Precision Medicine network to Locus Lab (São Paulo) for HER2 staining with automated protocols (Dako HercepTest and Roche Ventana 4B5) and scoring using different criteria (gastric cancer, breast cancer, and endometrial cancer). Primary objective is to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in endometrial, ovarian, and cervical cancers (common gynecological malignancies). Secondary objectives are to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in vulvar and vaginal cancers (rare gynecological malignancies); and to describe the prevalence of different HER2 expression levels (IHC 0, 1+ and 2+ using Dako HercepTest and gastric cancer scoring criteria) across all gynecological malignancies, to describe HER2 expression levels as per endometrial cancer scoring criteria in the endometrial cohort; to describe the association of different histological subtypes of gynecological cancer with HER2 IHC expression levels.

Full description

Retrospective molecular epidemiologic study.

Enrollment: 350 estimated patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >= 18 years at sample collection; - Diagnosis of cervical, endometrial, ovarian/peritoneum/uterine tube, vulvar, or vaginal cancers;
• Sufficient paraffin primary tumor tissue for biomarker testing in the OC Precision Medicine Pathology labs.
• Date of diagnosis of gynecological cancer must be from January 2020 to March 2025.
• Patients need to sign informed consent, or waiver of informed consent is granted.

Exclusion criteria

• Patients without sufficient paraffin tissue for the proposed biomarker testing.
• Patients whose diagnosis was performed in metastatic lesion.
• Patients with history of exposure to systemic anti-cancer therapies for the gynecological cancer diagnosis before surgery or excisional biopsy of gynecological cancer (information is available in the original histopathology request document stored in the LIMS).